ARS PHARMACEUTICALS INC(SPRY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SPRY ARS PHARMACEUTICALS INC

盘前交易 06-17 04:50:07 EDT

9.70

-0.11

-1.12%

盘前9.83

+0.13+1.34%

04:41 EDT

最高9.91	最低9.57	成交量87.48万
今开9.81	昨收9.81	日振幅3.47%
总市值9.59亿	流通市值5.36亿	总股本9,885万
成交额853.20万	换手率1.58%	流通股本5,527万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":9.7,"timestamp":1781640000000,"preClose":9.81,"halted":0,"volume":874818,"hourTrading":{"tag":"盘前","latestPrice":9.83,"preClose":9.7,"latestTime":"04:41 EDT","volume":3139,"amount":30816.363445,"timestamp":1781685675203,"change":0.13,"changeRate":0.013402,"amplitude":0.036082},"delay":0,"changeRate":-0.01121304791029574,"floatShares":55270496,"shares":98848611,"eps":-2.004377,"marketStatus":"盘前交易","change":-0.11,"latestTime":"06-17 04:50:07 EDT","open":9.81,"high":9.91,"low":9.57,"amount":8532049.214556,"amplitude":0.034659,"askPrice":10.62,"askSize":100,"bidPrice":9.7,"bidSize":130,"shortable":3,"etf":0,"ttmEps":-2.004377,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781703000000},"marketStatusCode":1,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":9.7,"preHourTrading":{"tag":"盘前","latestPrice":9.83,"preClose":9.7,"latestTime":"04:41 EDT","volume":3139,"amount":30816.363445,"timestamp":1781685675203,"change":0.13,"changeRate":0.013402,"amplitude":0.036082},"postHourTrading":{"tag":"盘后","latestPrice":9.6224,"preClose":9.7,"latestTime":"17:27 EDT","volume":1374,"amount":13281.1301,"timestamp":1781645243748,"change":-0.0776,"changeRate":-0.008,"amplitude":0.010309},"volumeRatio":0.763766102989103,"impliedVol":0.8547,"impliedVolPercentile":0.444},"requestUrl":"/m/hq/s/SPRY","defaultTab":"news","newsList":[{"id":"1143413101","title":"德鲁·布里斯携手ARS制药，提升严重过敏患者的生活质量意识","url":"https://stock-news.laohu8.com/highlight/detail?id=1143413101","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143413101?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:04","pubTimestamp":1780574686,"startTime":"0","endTime":"0","summary":"前NFL传奇四分卫德鲁·布里斯宣布与生物制药公司ARS Pharmaceuticals合作，共同发起一项旨在提高公众对严重过敏反应认知的倡议。该合作计划将聚焦于那些与严重过敏共存的个体，致力于推广相关的疾病教育，并探讨创新治疗方案如何改善患者的日常生活。布里斯以其卓越的体育生涯闻名，此次跨界合作凸显了他对公共卫生领域的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187836714","title":"ARS Pharmaceuticals：预计多数州级医疗补助计划将在2027年初前将Neffy纳入其无限制药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=1187836714","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187836714?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:06","pubTimestamp":1778839603,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals 预计，到2027年初，大多数州级医疗补助计划将把其药物Neffy纳入其无限制的医疗补助药品目录中。这一进展有望扩大该药物的覆盖范围和患者可及性，对公司未来市场拓展具有积极意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165973837","title":"ARS制药公司：CVS Caremark提案进入最终审批阶段，预计6月初发布明确更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1165973837","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165973837?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:04","pubTimestamp":1778839479,"startTime":"0","endTime":"0","summary":"ARS制药公司宣布，其与CVS Caremark的提案已进入审批流程的最后阶段。公司预计将在6月初提供一份明确的更新信息，以披露该提案的最终结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129690559","title":"ARS Pharmaceuticals任命行业资深人士Donn Casale为总裁，强化领导团队实力","url":"https://stock-news.laohu8.com/highlight/detail?id=1129690559","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129690559?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:03","pubTimestamp":1778673829,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals宣布任命行业资深人士唐·卡萨莱（Donn Casale）为公司总裁，此举旨在进一步强化其领导团队。\n卡萨莱在生物制药领域拥有丰富的管理经验，他的加入将为公司带来宝贵的行业洞见和战略领导力。此次人事任命体现了ARS Pharmaceuticals持续加强其管理层，以推动公司未来发展的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158905047","title":"ARS Pharmaceuticals Inc预计夏季前在加拿大提交Neffy 1毫克用于15-30公斤儿童的审批申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1158905047","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158905047?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:09","pubTimestamp":1776247779,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc计划于夏季前向加拿大监管机构提交其Neffy 1毫克产品的审批申请，该产品适用于体重在15至30公斤之间的儿童群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161492576","title":"ARS Pharmaceuticals Inc：Northland Capital 首次覆盖给予“跑赢大盘”评级，目标价25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161492576","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161492576?lang=zh_cn&edition=full","pubTime":"2026-04-09 19:47","pubTimestamp":1775735233,"startTime":"0","endTime":"0","summary":"Northland Capital 近日宣布对 ARS Pharmaceuticals Inc 启动研究覆盖，并给予“跑赢大盘”的积极评级。该机构同时设定了25美元的目标股价，显示出对公司未来增长潜力的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189355008","title":"ARS Pharmaceuticals获FDA批准移除Neffy® 1毫克（肾上腺素鼻喷雾剂）标签年龄限制","url":"https://stock-news.laohu8.com/highlight/detail?id=1189355008","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189355008?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:05","pubTimestamp":1774613127,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals公司宣布，其研发的Neffy 1毫克剂量肾上腺素鼻喷雾剂已获得美国食品药品监督管理局批准，将取消药品标签中的年龄使用限制。这一重要监管突破意味着该鼻喷雾剂未来可适用于更广泛的年龄群体，为不同年龄段患者提供更便捷的严重过敏反应应急治疗方案。移除年龄限制不仅拓宽了Neffy的适用人群，更凸显了ARS Pharmaceuticals在创新给药系统研发领域的技术实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618603224","title":"Ars Pharmaceuticals, Inc.2025财年实现净利润-1.71亿美元，同比减少2237.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618603224","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618603224?lang=zh_cn&edition=full","pubTime":"2026-03-10 06:00","pubTimestamp":1773093635,"startTime":"0","endTime":"0","summary":"3月10日，Ars Pharmaceuticals, Inc.公布财报，公告显示公司2025财年净利润为-1.71亿美元，同比减少2237.50%；其中营业收入为84.28百万美元，同比减少5.46%，每股基本收益为-1.74美元。从资产负债表来看，Ars Pharmaceuticals, Inc.总负债2.13亿美元，其中短期债务588000.00美元，资产负债比为1.54，流动比率为0.08。机构评级：截至2026年3月10日，当前有4家机构对Ars Pharmaceuticals, Inc.目标价做出预测，其中目标均价为27.50美元，其中最低目标价为12.00美元，最高目标价为34.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310060045a45c9176&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310060045a45c9176&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618603202","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘快速跳水5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618603202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618603202?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:06","pubTimestamp":1773065186,"startTime":"0","endTime":"0","summary":"北京时间2026年03月09日22时06分，Ars Pharmaceuticals, Inc.股票出现异动，股价急速下跌5.41%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。其相关个股中，Xenon制药、Relmada Therapeutics, Inc.、Atara Biotherapeutics, Inc.涨幅较大，Relmada Therapeutics, Inc.、Moolec Science Sa、Atara Biotherapeutics, Inc.较为活跃，换手率分别为35.41%、19.04%、18.11%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Biohaven Ltd.、An2 Therapeutics, Inc.，振幅分别为33.71%、28.63%、27.37%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030922062695461e1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030922062695461e1d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196337167","title":"ARS Pharmaceuticals公布2025年第四季度及全年财报，并更新Neffy®（肾上腺素鼻喷雾剂）商业化进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1196337167","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196337167?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:05","pubTimestamp":1773050705,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc（纳斯达克代码：SPRY）近日披露了2025年第四季度及全年的财务业绩，同时就旗下创新产品Neffy®（肾上腺素鼻喷雾剂）的商业化进程提供了最新动态。报告显示，公司在关键财务指标上达成预期目标，并为鼻喷雾剂的上市筹备工作制定了明确时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109964667","title":"ARS Pharmaceuticals Inc：Neffy在加拿大监管批准预计2026年第二季度 产品上市计划于2026年稍晚启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1109964667","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109964667?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:02","pubTimestamp":1773050549,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc宣布，其鼻喷式肾上腺素产品Neffy在加拿大的监管批准时间表已明确。根据最新规划，公司预计将在2026年第二季度获得加拿大卫生部的批准，随后于2026年晚些时候正式启动该产品的商业化上市。这一进展标志着ARS Pharmaceuticals在拓展北美市场方面迈出关键一步。若获批，它将成为加拿大市场上首款此类产品，有望改变当前依赖注射给药的过敏应急治疗格局。公司表示，已与加拿大监管机构就审批路径达成共识，并将按计划提交相关补充数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609219534","title":"Ars Pharmaceuticals, Inc.盘中异动 临近收盘快速跳水5.03%报9.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609219534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609219534?lang=zh_cn&edition=full","pubTime":"2026-02-06 04:53","pubTimestamp":1770324815,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日04时53分，Ars Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.03%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.67%。其相关个股中，Bone Biologics Corp C/Wts 13/10/2026 、Liminatus Pharma, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Propanc Biopharma, Inc.较为活跃，换手率分别为2057.86%、1263.43%、275.36%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Bone Biologics Corp C/Wts 13/10/2026 、Aim Immunotech Inc.，振幅分别为106.67%、70.70%、68.24%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206045335a4817dca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206045335a4817dca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186197538","title":"Eurneffy® 1毫克（肾上腺素鼻喷雾剂）获欧盟推荐批准，用于体重≥15公斤至＜30公斤儿童1型过敏反应（包括过敏性休克）的紧急治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1186197538","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186197538?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:03","pubTimestamp":1770037400,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Inc. 宣布，其产品Eurneffy® 1毫克（肾上腺素鼻喷雾剂）已获得欧盟人用药品委员会（CHMP）的积极意见，建议批准该药物用于体重在15公斤至30公斤以下（含15公斤，不含30公斤）的儿童患者，紧急治疗1型过敏反应，其中包括可能危及生命的过敏性休克。这一推荐标志着在儿童严重过敏应急治疗领域取得了一项重要进展，为小体重患儿提供了一种潜在的非注射给药选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603683635","title":"Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603683635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603683635?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:45","pubTimestamp":1768229110,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时45分，Ars Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.24%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.00%。其相关个股中，Cdt Equity Inc C/Wts 22/09/2028、Day One Biopharmaceuticals, Inc.、Forte Biosciences, Inc.涨幅较大，Jaguar Health, Inc.、Osr Holdings, Inc.、Genprex, Inc.较为活跃，换手率分别为538.92%、111.61%、48.15%，振幅较大的相关个股有Pyxis Oncology, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Geovax Labs, Inc.，振幅分别为26.42%、25.56%、24.64%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222451097a17707&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011222451097a17707&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128364104","title":"ARS Pharmaceuticals将获400万美元监管里程碑付款，并有望获得高达8000万美元销售里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1128364104","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128364104?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:04","pubTimestamp":1767013484,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals（纳斯达克代码：SPRY）近日宣布，公司将获得一笔400万美元的监管里程碑付款。此外，根据相关协议条款，该公司还有资格获得最高达8000万美元的销售里程碑款项。这一进展标志着公司在商业化进程中迈出重要一步，也为未来业绩增长提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199872730","title":"Neffy®（肾上腺素鼻喷雾剂）在华获批，成为首个且唯一可用于社区治疗的过敏反应（严重过敏）急救产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1199872730","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199872730?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:03","pubTimestamp":1767013385,"startTime":"0","endTime":"0","summary":"肾上腺素鼻喷雾剂Neffy®已正式获得中国监管部门的批准，该产品是首个且目前唯一获批用于社区场景、治疗过敏反应（严重过敏）的肾上腺素制剂。这一批准为患者提供了更为便捷和及时的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517461243","title":"ARS Pharmaceuticals(SPRY.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461243","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517461243?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:25","pubTimestamp":1741386325,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals(SPRY.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价30.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08062548605319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SPRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517398688","title":"Ars Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.01%报10.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517398688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517398688?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:18","pubTimestamp":1741119485,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时18分，Ars Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.01%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.07%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041805abe85197&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041805abe85197&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385185","title":"Ars Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.57%报10.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385185","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385185?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666704,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，Ars Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.57%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Quoin Pharmaceuticals Ltd涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为405.81%、90.91%、50.39%，振幅较大的相关个股有Pds Biotechnology Corporation、天演药业、Syros Pharmaceuticals, Inc.，振幅分别为11.69%、10.10%、10.09%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223144abdf6e9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223144abdf6e9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513377332","title":"Ars Pharmaceuticals, Inc.盘中异动 股价大跌5.16%报10.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513377332","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513377332?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:31","pubTimestamp":1740411117,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时31分，Ars Pharmaceuticals, Inc.股票出现波动，股价急速跳水5.16%。Ars Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为205.96%、86.70%、27.91%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Ars Pharmaceuticals, Inc.公司简介：ARS Pharmaceuticals Inc是一家生物制药公司，专注于开发用于紧急治疗 I 型过敏反应的新型、潜在全新候选产品 neffy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233158a25222ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224233158a25222ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":0.0308},{"period":"1month","weight":0.3064},{"period":"3month","weight":0.1687},{"period":"6month","weight":-0.0122},{"period":"1year","weight":-0.3602},{"period":"ytd","weight":-0.1674}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ARS Pharmaceuticals, Inc.于2016年1月4日根据特拉华州法律成立。该公司是一家生物制药公司，专注于开发新型、可能是一流的候选产品，neffy用于I型过敏反应的紧急治疗，包括过敏反应。neffy是一种肾上腺素的专有组合物，具有一种名为Intravail的创新吸收增强剂，允许neffy以小剂量、易于携带、易于使用、快速给药和可靠的鼻喷雾剂提供注射般的肾上腺素吸收。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.048654},{"month":2,"riseRate":0.5,"avgChangeRate":0.059864},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.043227},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.065084},{"month":5,"riseRate":0.833333,"avgChangeRate":0.033934},{"month":6,"riseRate":0.666667,"avgChangeRate":0.089445},{"month":7,"riseRate":0.8,"avgChangeRate":0.11695},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080641},{"month":9,"riseRate":0.2,"avgChangeRate":-0.212128},{"month":10,"riseRate":0.4,"avgChangeRate":-0.021216},{"month":11,"riseRate":0.4,"avgChangeRate":0.043601},{"month":12,"riseRate":0.6,"avgChangeRate":0.080317}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ARS PHARMACEUTICALS INC(SPRY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ARS PHARMACEUTICALS INC(SPRY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}